
Viking Therapeutics (VKTX) Stock Forecast & Price Target
Viking Therapeutics (VKTX) Analyst Ratings
Bulls say
Viking Therapeutics Inc. is positioned favorably within the expanding obesity treatment market due to its advancements in the VK2735 clinical program, which has shown promising weight loss results compared to competitors. The recent agreement with CordenPharma to secure large-scale manufacturing capacity for VK2735's active pharmaceutical ingredient and its formulations indicates a proactive approach to meeting anticipated market demand and enhances Viking's operational capabilities. Furthermore, the ongoing pursuit of opportunities in new therapeutic areas such as Alzheimer's and hypertension, alongside the positive continuum of cardiovascular outcome trial data, bolsters confidence in long-term value creation driven by its product pipeline.
Bears say
Viking Therapeutics Inc's financial outlook is negatively impacted by increased research and development spending, which has led to a downward adjustment in the price target from $109 to $96. Key concerns include the potential for negative safety or efficacy findings in late-stage clinical trials that could further lower projections and generate uncertainty about market penetration and sales revenue for its candidates. Additionally, the company's fourth quarter earnings per share fell short of estimates, highlighting ongoing financial challenges and doubts regarding the successful advancement of its clinical programs.
This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viking Therapeutics (VKTX) Analyst Forecast & Price Prediction
Start investing in Viking Therapeutics (VKTX)
Order type
Buy in
Order amount
Est. shares
0 shares